Literature DB >> 26632636

Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review.

Anca Lădaru1,2, Paul Bălănescu3,4, Mihaela Stan1,2, Ioana Codreanu1,2, Ioana Alina Anca1,2.   

Abstract

CONTEXT: Non-alcoholic fatty liver disease (NAFLD) is characterized by lipid accumulation in the liver which is accompanied by a series of metabolic deregulations. There are sustained research efforts focusing upon biomarker discovery for NAFLD diagnosis and its prognosis in order investigate and follow-up patients as minimally invasive as possible.
OBJECTIVE: The objective of this study is to critically review proteomic studies that used mass spectrometry techniques and summarize relevant proteomic NAFLD candidate biomarkers.
METHODS: Medline and Embase databases were searched from inception to December 2014.
RESULTS: A final number of 22 records were included that identified 251 candidate proteomic biomarkers. Thirty-three biomarkers were confirmed - 14 were found in liver samples, 21 in serum samples, and two from both serum and liver samples.
CONCLUSION: Some of the biomarkers identified have already been extensively studied regarding their diagnostic and prognostic capacity. However, there are also more potential biomarkers that still need to be addressed in future studies.

Entities:  

Keywords:  Biomarker; mass-spectrometry; non-alcoholic fatty liver disease; proteomics

Mesh:

Substances:

Year:  2015        PMID: 26632636     DOI: 10.3109/1354750X.2015.1118542

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  10 in total

Review 1.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

Review 2.  Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review.

Authors:  Natalia Rosso; Adam M Stephenson; Pablo J Giraudi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2021-04

Review 3.  Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease.

Authors:  Manuel Suárez; Noemí Boqué; Josep M Del Bas; Jordi Mayneris-Perxachs; Lluís Arola; Antoni Caimari
Journal:  Nutrients       Date:  2017-09-22       Impact factor: 5.717

4.  Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease.

Authors:  Prahlad K Rao; Kate Merath; Eugene Drigalenko; Avinash Y L Jadhav; Richard A Komorowski; Matthew I Goldblatt; Anand Rohatgi; Mark A Sarzynski; Samer Gawrieh; Michael Olivier
Journal:  Clin Proteomics       Date:  2018-03-06       Impact factor: 3.988

5.  A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.

Authors:  G Craig Wood; Xin Chu; George Argyropoulos; Peter Benotti; David Rolston; Tooraj Mirshahi; Anthony Petrick; John Gabrielson; David J Carey; Johanna K DiStefano; Christopher D Still; Glenn S Gerhard
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 6.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

Review 7.  Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.

Authors:  Maria Grazia Clemente; Claudia Mandato; Marco Poeta; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

Review 8.  Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.

Authors:  Xuelin Zhang; Yang Wang; Pingsheng Liu
Journal:  Protein Cell       Date:  2016-10-18       Impact factor: 14.870

9.  Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study.

Authors:  Anca Bălănescu; Iustina Stan; Ioana Codreanu; Valentina Comănici; Eugenia Bălănescu; Paul Bălănescu
Journal:  Dis Markers       Date:  2019-12-03       Impact factor: 3.434

10.  Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study.

Authors:  Anca Bălănescu; Ioana Florentina Codreanu; Valentina Daniela Comanici; Iustina Violeta Stan; Eugenia Bălănescu; Paul Bălănescu
Journal:  Biomed Res Int       Date:  2020-08-17       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.